459 Anti-CCR4 monoclonal antibody, mogamulizumab (Moga), demonstrates superior efficacy compared to vorinostat (Vor) in patients with previously treated cutaneous T-cell lymphoma (CTCL): results of the phase 3 MAVORIC study